Most Common Severe Side Effects of Yervoy
Yervoy (ipilimumab), a Bristol Myers Squibb immunotherapy for melanoma and other cancers, triggers immune-related adverse events by overactivating the immune system against healthy tissues. Severe (Grade 3-4) side effects, occurring in over 10% of patients in clinical trials, include colitis (diarrhea with ulceration), hepatitis (liver inflammation), dermatitis (severe skin rash), and endocrinopathies like hypophysitis (pituitary inflammation).[1][2]
Enterocolitis and Diarrhea Risks
Enterocolitis affects up to 34% of patients severely, leading to perforation, bleeding, or ileus requiring hospitalization or surgery. Symptoms start within weeks of infusion; fatal cases occur in 1-2%.[1][3]
Liver Toxicity Details
Hepatitis strikes 5-15% severely, with elevated liver enzymes (AST/ALT >10x upper limit), jaundice, and potential fulminant failure. Monitor LFTs every 2-3 weeks; steroids treat most cases.[2][4]
Skin Reactions Patients Report
Severe dermatitis or Stevens-Johnson syndrome hits 2-10%, with blistering, ulceration, or toxic epidermal necrolysis. Pruritus precedes rash; biopsy confirms immune infiltrate.[1][3]
Endocrine Disruptions and Hypophysitis
Hypophysitis (8% severe) causes headaches, fatigue, vision changes, and hormone deficiencies (adrenal, thyroid). MRI detects pituitary enlargement; lifelong replacement therapy often needed.[2][4]
Pneumonitis and Other Organ Involvement
Pneumonitis (1-5% severe) presents as dyspnea and infiltrates; other rares include myocarditis, Guillain-Barré syndrome, or encephalitis, with fatality risks up to 1% combined.[1][3]
What Happens in Combination Therapy?
With Opdivo (nivolumab), severe events rise to 50-60%, especially colitis (20%) and hepatitis (15%). Onset quicker; manage with higher-dose steroids or infliximab.[2][4]
Management and When to Seek Care
Discontinue for Grade 3-4; hold for Grade 2. Immune checkpoint inhibitors like Yervoy demand vigilant monitoring—report abdominal pain, persistent diarrhea, or yellowing skin immediately. No specific antidote exists.[1][3]
[1]: Yervoy Prescribing Information (FDA)
[2]: Bristol Myers Squibb Yervoy Safety Data
[3]: NCCN Guidelines: Melanoma (Version 2.2024)
[4]: ASCO Post: Ipilimumab Toxicity Review